Literature DB >> 10659668

Hepatitis B seroprevalence in Latin America.

T R Silveira1, J C da Fonseca, L Rivera, O H Fay, R Tapia, J I Santos, E Urdeneta, S A Clemens.   

Abstract

The seroprevalence of hepatitis B was investigated in over 12,000 subjects in six countries of Latin America: Argentina, Brazil, Chile, the Dominican Republic, Mexico, and Venezuela. Each study population was stratified according to age, gender, and socioeconomic status. Antibodies against hepatitis B core antigen (anti-HBc) were measured in order to determine hepatitis B infection. The highest overall seroprevalence was found in the Dominican Republic (21.4%), followed by Brazil (7.9%), Venezuela (3.2%), Argentina (2.1%), Mexico (1.4%), and Chile (0.6%). In all the countries an increase in seroprevalence was found among persons 16 years old and older, suggesting sexual transmission as the major route of infection. In addition, comparatively high seroprevalence levels were seen at an early age in the Dominican Republic and Brazil, implicating a vertical route of transmission.

Entities:  

Mesh:

Year:  1999        PMID: 10659668     DOI: 10.1590/s1020-49891999001100002

Source DB:  PubMed          Journal:  Rev Panam Salud Publica        ISSN: 1020-4989


  8 in total

1.  Prevalence and factors associated with HSV-2 and hepatitis B infections among truck drivers crossing the southern Brazilian border.

Authors:  Adriana A Pinho; Magda Chinaglia; Sheri A Lippman; Arthur Reingold; Ricardo Sobhie Diaz; Maria Cecilia Sucupira; Kimberly Page; Juan Díaz
Journal:  Sex Transm Infect       Date:  2011-10-03       Impact factor: 3.519

2.  A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review.

Authors:  Sonia Roman; Arturo Panduro; Yadira Aguilar-Gutierrez; Montserrat Maldonado; Maclovia Vazquez-Vandyck; Erika Martinez-Lopez; Bertha Ruiz-Madrigal; Zamira Hernandez-Nazara
Journal:  Hepatol Int       Date:  2008-12-19       Impact factor: 6.047

3.  Serologic and molecular profile of anti-HBc-positive blood bank donors in an area of low endemicity for HBV.

Authors:  Carlos Kupski; Felipe R Träsel; Felipe Mazzoleni; Marco A Winckler; Ana Ligia Bender; Denise C Machado; Virgínia M Schmitt
Journal:  Dig Dis Sci       Date:  2007-10-12       Impact factor: 3.199

Review 4.  Occult HBV infection: a faceless enemy in liver cancer development.

Authors:  Jaime Morales-Romero; Gustavo Vargas; Rebeca García-Román
Journal:  Viruses       Date:  2014-04-08       Impact factor: 5.048

5.  Hepatitis B sero-prevalence and risk behaviors among immigrant men in a population-based household survey in low-income neighborhoods of northern California.

Authors:  Vivian Levy; Jinwei Yuan; Juan Ruiz; Scott Morrow; Juan Reardon; Mathew Facer; Fred Molitor; Barbara Allen; Barbara Green Ajufo; Geneva Bell-Sanford; Willi McFarland; Henry F Raymond; Tim Kellogg; Kimberly Page
Journal:  J Immigr Minor Health       Date:  2009-03-25

6.  Risk factors for hepatitis B virus infection in Rio de Janeiro, Brazil.

Authors:  Lia L Lewis-Ximenez; Kycia M R do O; Cleber F Ginuino; Jucimara C Silva; Hermann G Schatzmayr; Sherri Stuver; Clara F T Yoshida
Journal:  BMC Public Health       Date:  2002-11-22       Impact factor: 3.295

7.  Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors.

Authors:  Gretchen Stevens; Rodrigo H Dias; Kevin J A Thomas; Juan A Rivera; Natalie Carvalho; Simón Barquera; Kenneth Hill; Majid Ezzati
Journal:  PLoS Med       Date:  2008-06-17       Impact factor: 11.069

8.  Population-Based Multicentric Survey of Hepatitis B Infection and Risk Factors in the North, South, and Southeast Regions of Brazil, 10-20 Years After the Beginning of Vaccination.

Authors:  Ricardo A A Ximenes; Gerusa M Figueiredo; Maria Regina A Cardoso; Airton T Stein; Regina C Moreira; Gabriela Coral; Deborah Crespo; Alex A Dos Santos; Ulisses R Montarroyos; Maria Cynthia Braga; Leila M M B Pereira
Journal:  Am J Trop Med Hyg       Date:  2015-10-26       Impact factor: 2.345

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.